Andrew Johnson

Andrew Johnson, MD, is an experienced medical professional currently serving as Executive Director and Head of Medical Strategy in Global Medical and Scientific Affairs at Karyopharm Therapeutics Inc. since 2023. Prior to this role, Andrew held the position of Medical Director in US Medical Affairs at Ipsen from 2021 to 2023 and Associate Director of Medical Affairs at Puma Biotechnology, Inc. from 2020 to 2021. Andrew's career includes significant roles at AstraZeneca from June 2017 to December 2019, where responsibilities ranged from Patient Safety and Medical Information to Acting Medical Adviser and Medical Science Liaison. Additionally, Andrew contributed as a part-time Instructor at the Academy of Applied Pharmaceutical Sciences between 2018 and 2019. Earlier experiences also include a Medical Oncologist Sub-Internship at MedStar Union Memorial Hospital and a comprehensive medical education, culminating in a Doctor of Medicine degree from International American University in 2016 and a Bachelor’s Degree in Biology and Physics from Brock University in 2012.